AI assistant
BIOTRON LIMITED — Capital/Financing Update 2026
Jan 29, 2026
64528_rns_2026-01-29_8c67d2d4-6992-44e6-9326-10e71d95d0a0.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
Biotron Limited
ACN 086 399 144
SUPPLEMENTARY PROSPECTUS
Important Information
This is a supplementary prospectus ( Supplementary Prospectus ) intended to be read with the prospectus dated 18 November 2025 ( Prospectus ) issued by Biotron Limited ( Company ).
This Supplementary Prospectus is dated 30 January 2026 and was lodged with the Australian Securities and Investments Commission ( ASIC ) on that day. Neither ASIC nor ASX (and their respective officers) take any responsibility as to the contents of this Supplementary Prospectus.
To the extent of any inconsistency between this Supplementary Prospectus and the Prospectus, this Supplementary Prospectus will prevail. Unless otherwise indicated, terms defined and used in the Prospectus have the same meaning in this Supplementary Prospectus.
This is an important document and should be read in its entirety. If you do not understand it you should consult your professional advisors without delay.
1 REVISED TIMETABLE
On 23 December 2025 Dr Paul Kasian was appointed a Director of the Company with immediate effect.
On 30 January 2026 the Company issued the following securities under the Prospectus, being Shortfall:
| On 30 January 2026 the Company issued the following securities underShortfall: | the Prospectus, being |
|---|---|
| Shares | 292,666,664 |
| Attaching Options ($0.02 expiring 24 November 2027, ticker BITO) | 146,333,324 |
The Offer and Shortfall Offer have now been fully subscribed, and no further securities will be issued under the Prospectus.
The Directors do not consider the circumstances disclosed in this Supplementary Prospectus to be materially adverse from the point of view of an investor, and no withdrawal rights will be offered to investors.
This Supplementary Prospectus is issued by the Company, and its issue has been authorised by a resolution of the Directors. In accordance with section 720 of the Corporations Act, each Director has consented to the lodgment of this Supplementary Prospectus with ASIC.
Dated: 30 January 2026
==> picture [122 x 52] intentionally omitted <==
..................................
Signed for and on behalf of Biotron Limited By Dr Michelle Miller Managing Director
pjn12849 Prospectus - supplementary 30 January 2026